Download the Flyer
Learn about the latest in translational bioengineering and how it can be translated for clinical and industrial applications in this special seminar.
Special Seminar: Emerging Technologies and Biomedical Engineering Innovation
Presented by Martin L. Yarmush MD, PhD
Monday, October 7, 2019
10–11 a.m.
Goldwater Center (GWC) 487, Tempe campus [map]
This presentation will briefly describe several topics that fall within the province of translational bioengineering, including dynamic cell and tissue microsystems; cellular therapeutics and organ engineering and storage. Emphasis will be placed on the significance of the work including the intended scientific and technological gaps to be filled, and the opportunities for translating the work to the clinical and industrial realms.
About the speaker
Professor Martin L. Yarmush is an internationally recognized bioengineer and translational scientist who has been a leader in the fields of tissue engineering and regenerative medicine, BioMEMS and nanotechnology, applied immunology and biotechnology, metabolic engineering, and medical device development. Professor Yarmush currently serves as the Paul and Mary Monroe Chair and Distinguished Professor of Biomedical Engineering at Rutgers, and the Director of the Center for Engineering in Medicine at the Massachusetts General Hospital/Harvard Medical School. Over the last 40 years, Yarmush has published more than 500 refereed journal articles and more than 50 patents and patent applications. He has mentored more than 60 graduate students and more than 120 postdoctoral fellows, and taught a spectrum of courses from molecular genetics, biochemistry, and immunology, to thermodynamics and transport phenomena, to advanced biotechnology and innovation and entrepreneurship.
Yarmush’s contributions to his field through service include serving as a member of NIH, NSF, FDA, and Office of Technology Assessment review panels; an advisory board member for foundations (e.g. the Whitaker Foundation, Juvenile Diabetes Foundation, and Doris Duke Foundation), academic-based centers, and industrial firms; and an editor of numerous science and engineering journals, including the Annual Review of Biomedical Engineering, the #1 journal in impact factor in its peer group for 16 years. He has been credited with many pioneering scientific and technological advances including: innovative cell culture systems and tissue engineering constructs, stem cell therapies, venous access devices, dynamic cell and tissue microsystems, pulsed electric field therapies, bioartificial organs development, targeted therapies for tumors and infections, recombinant protein purification techniques, and recombinant retrovirus production and purification techniques.
